BriaCell Therapeutics Corp 6-K, filed Jul 12, 2021

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

---

---

FORM6-K

---

---

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2021

Commission File Number: 001-40101

---

---

BRIACELLTHERAPEUTICS CORP.

(Translation of registrant’s name into English)

---

---

Suite300 – 235 15^th^ Street

WestVancouver, BC V7T 2X1

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

---

---

---

Exhibit Number	Description
99.1	Press Release, dated July 12, 2021, issued by BriaCell Therapeutics Corp.

---

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BriaCell Therapeutics Corp.
Date:<br> July 12, 2021	By:	/s/ William V. Williams
	Name:	William<br> V. Williams
	Title:	Chief<br> Executive Officer

Exhibit99.1

---

BriaCellto Present at Three Upcoming Investor Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell”or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the following virtual conferences:

●	Access to Giving Virtual Investor conference: July 13 – 15, 2021
○	Dr.<br> Williams will be speaking at the conference at 2:30pm ET on July 14, 2021.
---	---
○	Management<br> will be available for one-on-one meetings to be held throughout the conference.
○	The<br> presentation will be webcast live and available for replay at Webcast URL.
○	For<br> additional information on the conference, please visit: https://www.accesstogiving.com/.
●	Q3 Investor Summit: August 17 – 18, 2021
---	---
○	Dr.<br> Williams will deliver his corporate presentation at 1:15pm ET on August 17, 2021.
---	---
○	Investors<br> may request one-on-one meetings with Dr. Williams.
○	Investors<br> may register for the conference here: https://investorsummitgroup.com/.
●	SNN Network Summer Virtual Event Investor Conference: August 17 – 19, 2021
---	---
○	Dr.<br> Williams will deliver his corporate presentation at 10:30am ET on August 18, 2021.
---	---
○	Investors<br> may request one-on-one meetings with Dr. Williams.
○	Investors<br> may register for the conference here: https://conference.snn.network/.

AboutBriaCell Therapeutics Corp.

---

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

---

SafeHarbor

---

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

---

ContactInformation

CompanyContact:

William V. Williams, MD

President & CEO

1-888-485-6340

info@briacell.com

MediaRelations:

Jules Abraham

Director of Public Relations

CORE IR

917-885-7378

julesa@coreir.com

InvestorRelations Contact:

CORE IR

investors@briacell.com